Medicare Part D Coverage of Antiobesity Medications — Challenges and Uncertainty Ahead
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Interview with Dr. Ashley Leech on the potential implications of Medicare Part D covering medications for obesity treatment. (11:22)Download Medicare could soon be compelled to cover antiobesity medications, which intensifies the need to address questions of effectiveness and cost among its beneficiaries.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, limited payer coverage of antiobesity medications and off-label use of antidiabetes medications, including GLP-1 RAs, still represents a major challenge for many patients.16,17,18”
From Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity (2025) · cites this paper as [16]
Citations
Cites
Association of body mass index with health care expenditures in the united states by age and sex
Ward, Z. J., Bleich, S. N., Long, M. W., & Gortmaker, S. L. (2021) · PLOS ONE · doi:10.1371/journal.pone.0247307 · Cited by 428
Risk of Progression to Diabetes Among Older Adults With Prediabetes
Rooney, M. R., Rawlings, A. M., Pankow, J. S., Echouffo Tcheugui, J. B., Coresh, J., Sharrett, A. R., & Selvin, E. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.8774 · Cited by 174
Dorner, B., & Friedrich, E. K. (2018) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2018.01.022 · Cited by 103
Research works printed but not linked: 1
- Atlas SJ Kim K Beinfeld M et al. Obesity management: an assessment of subcutaneous semaglutide phentermine/topiramate and naltrexone/bupropion. Boston: Institute for Clinical and Economic Review October 20 2022 (https://icer.org/assessment/obesity-management-2022/).
Cited by
Ng, M., Dai, X., Cogen, R. M., Abdelmasseh, M., Abdollahi, A., Abdullahi, A., Aboagye, R. G., Abukhadijah, H. J., Adeyeoluwa, T. E., Afolabi, A. A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01548-4 · Cited by 344
“78,119,120 The past adoption trends of treatments for other metabolic diseases, such as statins for dyslipidaemia, suggest that although prescription volumes increased after introducing cheaper generic options, 121 considerable underutilisation remains in susceptible populations.”
Lingvay, I., Cohen, R. V., Roux, C. W. L., & Sumithran, P. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01210-8 · Cited by 433
Rodriguez, P. J., Zhang, V., Gratzl, S., Do, D., Goodwin Cartwright, B., Baker, C., Gluckman, T. J., Stucky, N., & Emanuel, E. J. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.57349 · Cited by 374
Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022.
Watanabe, J. H., Kwon, J., Nan, B., & Reikes, A. (2024) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2023.10.002 · Cited by 216
Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia
Sen, S., Potnuru, P. P., Hernandez, N., Goehl, C., Praestholm, C., Sridhar, S., & Nwokolo, O. O. (2024) · JAMA Surgery · doi:10.1001/jamasurg.2024.0111 · Cited by 202
Wadden, T. A., Chao, A. M., Moore, M., Tronieri, J. S., Gilden, A., Amaro, A., Leonard, S., & Jakicic, J. M. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00534-z · Cited by 129
“This will include reducing the high costs of these medications [119] and assuring their coverage by public and private insurers [120].”
BackgroundSemaglutide vs endoscopic sleeve gastroplasty for weight loss
Haseeb, M., Chhatwal, J., Xiao, J., Jirapinyo, P., & Thompson, C. C. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.6221 · Cited by 73
Patents and regulatory exclusivities on GLP-1 receptor agonists
Alhiary, R., Kesselheim, A. S., Gabriele, S., Beall, R. F., Tu, S. S., & Feldman, W. B. (2023) · JAMA · doi:10.1001/jama.2023.13872 · Cited by 67
Effectiveness and safety of drugs for obesity
Henderson Lewis, K., Sloan, C. E., Bessesen, D. H., & Arterburn, D. (2024) · BMJ · doi:10.1136/bmj-2022-072686 · Cited by 66
“66-69 • In 2015-2016, among 7378 adults surveyed about their employer based insurance, 21% reported having coverage for antiobesity medications.”
BackgroundQuarenghi, M., Capelli, S., Galligani, G., Giana, A., Preatoni, G., & Quarenghi, R. T. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113791 · Cited by 65
“This is a fundamental issue, given the high costs of these treatments [32].”
Evidence for the contribution of the gut microbiome to obesity and its reversal
de Wit, D. F., Hanssen, N. M. J., Wortelboer, K., Herrema, H., Rampanelli, E., & Nieuwdorp, M. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adg2773 · Cited by 51
“Brand-name semaglutide costs around $13,000 annually in the United States, and 10% use in obese individuals 60 years or older would cost an estimated $26.8 billion, or 18% of the Medicare drug coverage budget ( 90 ).”
BackgroundInfluentialState coverage and reimbursement of antiobesity medications in Medicaid.
Liu, B. Y., & Rome, B. N. (2024) · JAMA · doi:10.1001/jama.2024.3073 · Cited by 46
Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity
Hwang, J. H., Laiteerapong, N., Huang, E. S., Mozaffarian, D., Fendrick, A. M., & Kim, D. D. (2025) · JAMA Health Forum · doi:10.1001/jamahealthforum.2025.0905 · Cited by 43
Self-citationCost-Effectiveness of Antiobesity Drugs for Adolescents With Severe Obesity
Mital, S., & Nguyen, H. V. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.36400 · Cited by 41
Prescription Fills for Semaglutide Products by Payment Method
Scannell, C. A., Romley, J. A., Myerson, R. M., Goldman, D. P., & Qato, D. M. (2024) · JAMA Health Forum · doi:10.1001/jamahealthforum.2024.2026 · Cited by 38
Grunstein, R. R., Wadden, T. A., Chapman, J. L., Malhotra, A., & Phillips, C. L. (2023) · SLEEP · doi:10.1093/sleep/zsad224 · Cited by 36
How Weight Bias and Stigma Undermine Healthcare Access and Utilization
Pearl, R. L., & Sheynblyum, M. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00605-3 · Cited by 38
“Relatedly, insurance coverage of these medications for the treatment of obesity in the U.S. is currently restricted, due largely to cost [87], but also due in part to their designation by Medicare as a “cosmetic” rather than medical treatment [88].”
Net prices of new antiobesity medications
Hernandez, I., & Sullivan, S. D. (2024) · Obesity · doi:10.1002/oby.23973 · Cited by 22
“Specifically, arguments against insurance coverage of GLP1s have centered on their failure to meet commonly accepted cost-effectiveness thresholds and their expected budget impact at current prices [5, 6].”
BackgroundA Real-World Study of the Effectiveness and Safety of Semaglutide for Weight Loss
Tzoulis, P., Batavanis, M., & Baldeweg, S. E. (2024) · Cureus · doi:10.7759/cureus.59558 · Cited by 30
“However, state insurance coverage in most countries has excluded the use of AOMs, while international health technology assessment agencies have made conflicting recommendations about the reimbursement of AOMs based on their long-term cost-effectiveness [26].”
BackgroundComprehensive care for patients with obesity: An Obesity Medicine Association Position Statement
Fitch, A., Alexander, L., Brown, C. F., & Bays, H. E. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100070 · Cited by 24
Semaglutide: a new drug for the treatment of obesity
Lexchin, J., & Mintzes, B. J. (2023) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2023.000007 · Cited by 27
Kim, D. D., Hwang, J. H., & Fendrick, A. M. (2024) · Health Affairs Scholar · doi:10.1093/haschl/qxae055 · Cited by 21
Self-citationAnti-obesity pharmacotherapy in adults with chronic kidney disease
Taber-Hight, E., Gilmore, A. C., & Friedman, A. N. (2023) · Kidney International · doi:10.1016/j.kint.2023.10.014 · Cited by 22
Jolin, J. R., Kwon, M.-S., Brock, E. M., CHEN, J., KOKAN, A., Murdock, R., & Stanford, F. C. (2024) · Milbank Quarterly · doi:10.1111/1468-0009.12693 · Cited by 20
Medical Nutrition Therapy: Still Relevant in the Era of Pharmacotherapy for Obesity Care
Miller, C. K. (2025) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2024.06.222 · Cited by 19
Lessons From Insulin: Policy Prescriptions for Affordable Diabetes and Obesity Medications
Nagel, K. E., Ramachandran, R., & Lipska, K. J. (2024) · Diabetes Care · doi:10.2337/dci23-0042 · Cited by 20
O’Leary, S., Price, A., Camarillo‐Rodriguez, L., Costa, M. L., Karas, P. J., Young, C. C., Srinivasan, V. M., & Kan, P. T. M. (2025) · Journal of neurosurgery · doi:10.3171/2025.1.jns242357 · Cited by 25
Medicare Part D Coverage of Anti-obesity Medications: a Call for Forward-Looking Policy Reform
Hernandez, I., Wright, D. R., Guo, J., & Shrank, W. H. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-023-08416-9 · Cited by 18
Access to GLP-1 weight loss drugs in the US, Canada, Switzerland, and Germany.
Vokinger, K. N., Nussli, E., & Dusetzina, S. B. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.2559 · Cited by 18
Self-citationMedicare Coverage and Patient Out-of-Pocket Costs for Cardiovascular-Kidney-Metabolic Medications
Young, G. M., Bansal, K., Riello, R. J., Clark, K. A. A., Dhruva, S. S., Faridi, K. F., & Desai, N. R. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.12437 · Cited by 16
Muniyappa, R., Chukir, T., Desai, D., Weintraub, M. A., Corrigan, M. D., Gianchandani, R. Y., & Rothberg, A. E. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag097 · Cited by 16
Ippolito, B., & Levy, J. F. (2024) · Health Affairs · doi:10.1377/hlthaff.2024.00356 · Cited by 14
Treating class 2–3 obesity with glucagon‐like peptide‐1 agonists: A 2‐year real‐world cohort study
Abdel‐Bary, M., Brody, A., Schmitt, J., Prieto, K., Wetzel, A. N., & Juo, Y. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16331 · Cited by 13
“Obesity is one of the most formidable public health crises in the United States, affecting approximately 40% of the population.”
Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial
Lusk, J. B., Glover, L., Soneji, S., Granger, C. B., O'Brien, E., & Pagidipati, N. (2024) · American Heart Journal · doi:10.1016/j.ahj.2024.05.007 · Cited by 9
Aneke-Nash, C. S., Hung, K. S., Wall‐Wieler, E., Zheng, F., & Sharaiha, R. Z. (2025) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2024-001704 · Cited by 9
Understanding Insurance Coverage Policies for Incretin Mimetics for Weight Management
Griauzde, D., Carter, E. W., Oshman, L., Gabison, J., Kraftson, A., Fendrick, A. M., & Lott, S. (2025) · The American Journal of Managed Care · doi:10.37765/ajmc.2025.89685 · Cited by 8
Ostrominski, J. W., Wagholikar, K. B., Olsson, K., Ünlü, O., Zelle, D., Kumar, S., Smith, A. M., Toliver, J. C., Michalak, W., Fabricatore, A. N., et al. (2024) · Obesity · doi:10.1002/oby.24186 · Cited by 8
Older Adults’ Views on Insurance Coverage for Weight Management Medications
Oshman, L. D., Kirch, M., Solway, E. S., Singer, D., Malani, P., Roberts, J. S., Kullgren, J. T., & Hafez, D. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.2008 · Cited by 7
Turning CMS into a Health Technology Assessment Organization
Neumann, P. J., & Tunis, S. R. (2023) · New England Journal of Medicine · doi:10.1056/nejmp2305280 · Cited by 7
Nguyen, T. K., Wong, E., & Cope, R. J. (2023) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001643 · Cited by 8
Metabolic polygenic risk scores for prediction of obesity, type 2 diabetes, and related morbidities
Kim, M. S., Chen, Q., Sui, Y., Yang, X., Wang, S., Weng, L.-C. C., Cho, S. M. J., Koyama, S., Zhu, X., Yu, K., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.02.009 · Cited by 7
A novel gene therapy platform for the treatment of type 2 diabetes and obesity
Lourie, J., Goraltchouk, A., Hollander, J. M., BERGER, N. J. A., Rosen, H. G., Fujishiro, A. A., Luppino, F., Seregin, A., Rhym, L. H., & Zou, K. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102739 · Cited by 6
“21,22 The current treatment paradigm also incurs significant costs for healthcare infrastructure, with potential to reach $26.8 billion in annual Medicare benefit spending in the US alone 23–25 if coverage is expanded to include obesity.”
InfluentialRaza, S. S., Zakir, Z., Hashmat, A., Awan, S. K., & Varrassi, G. (2025) · Cureus · doi:10.7759/cureus.96739 · Cited by 8
“Coverage still remains plan-specific and inconsistent [15-17].”
Challenges in the management of obesity
Smith, B. L., May, A., Lalani, F., Hasham, S., & Presnell, A. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.09.023 · Cited by 4
Amirthalingam, P., Alatawi, O. S., Hamdan, A. M., Aljabri, A. M., Alqifari, S. F., Alshareef, H. M., Hakami, F. A. M., Albalawi, N. S., Albrahimi, H. M. A., Alanazi, S., et al. (2025) · Patient Preference and Adherence · doi:10.2147/ppa.s534534 · Cited by 4
“21,22 Such supply and refilling issues can be assessed using a self-reported questionnaire; the Adherence to Refills and Medications Scale (ARMS) consists of 12 items divided into two domains: refilling prescriptions and medication adherence, and performs well across various literacy levels.”
Linking Obesity, Metabolism, and Cancer
Vučenik, I., Jones, L. P., & McLenithan, J. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_50 · Cited by 5
Weight Loss Outcomes in a Veterans Affairs Pharmacotherapy-based Weight Management Clinic
Ni, K., Rogowitz, E., Farahmand, A., Grau, L., Arbet, J., Cunningham, C. R., Thomas, E. A., & Saxon, D. R. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae042 · Cited by 3
“Last, real-world outcomes from VHA patient cohorts can potentially guide Congressional and Centers for Medicare & Medicaid Services’ review of AOM coverage guidelines [24] given overlapping VHA and Medicare patient populations [25].”
BackgroundBays, H. E., Brown, C., & Fitch, A. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100079 · Cited by 3
Projected prescription drug expenditures in 2024: Looking ahead to the inflation reduction era
Hernandez, I. (2024) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxae104 · Cited by 3
Cho, Y. K., & Jung, C. H. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0744 · Cited by 5
Qiu, C. X., Chen, Q., Tovar, S., Kwok, K. K., Conte, A. T. H., Ferrara, J. T., Desai, V. N., Shi, J. M., Giap, A. Q., & Wu, B. U. (2025) · Gastro Hep Advances · doi:10.1016/j.gastha.2025.100869 · Cited by 2
“18,19 Combined with emerging evidence of their clinical effectiveness on many chronic conditions such as obesity and DM, the patterns, trends, and prevalence of GLP-1RA use have been changing.”
GLP-1 Receptor Agonist Coverage for Obesity in Medicaid and Total GLP-1 Receptor Agonist Utilization
Khanna, R., Wang, M. C., & Venkataramani, A. S. (2026) · JAMA Health Forum · doi:10.1001/jamahealthforum.2026.3353 · Cited by 2
Endoluminal bariatric and metabolic therapies: state-of-the-art
Bakheet, N. G., Badurdeen, D., Sartoretto, A., & Kumbhari, V. (2023) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000967 · Cited by 2
Watanabe, J. H. (2023) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2023.493 · Cited by 2
Linking Obesity, Metabolism, and Cancer
Vučenik, I., Jones, L. P., & McLenithan, J. C. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_50-2 · Cited by 2
Parums, D. V. (2024) · Medical Science Monitor · doi:10.12659/msm.946675 · Cited by 2
(2024) · The American Journal of Managed Care · doi:10.37765/ajmc.2024.89586 · Cited by 1
Self-citationMeron, M. K., Koren‐Morag, N., & Oieru, D. (2024) · Obesity Facts · doi:10.1159/000542080 · Cited by 1
“Studying the clinical impact of OW/OB diagnosis per se is important for public health, especially given the high prevalence of OW/OB, high cost of drug therapy and limited coverage of anti-obesity medications by payers [13, 14].”
Rothberg, A. E., Ye, W., Miller, N., & Rizza, R. A. (2025) · Obesity Science & Practice · doi:10.1002/osp4.70092 · Cited by 1
“As a result, coverage is highly variable among health plans [19, 20] and the medications are not covered by Medicare for obesity.”
Eligibility for Anti-Obesity Medications Among Medicare Beneficiaries with Overweight or Obesity
Chetty, A. K., Khunte, M., Chen, A. S., Jastreboff, A. M., Krumholz, H. M., & Lu, Y. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-09178-8 · Cited by 1
Financial buy-in does not affect outcomes of endoscopic sleeve gastroplasty: Retrospective cohort
Sayegh, L. N., Akiki, K., Annan, K. A., Salameh, Y., Gala, K. S., Mosleh, K. A., Mundi, M. S., Ghanem, O. M., Dayyeh, B. K. A., & Storm, A. C. (2025) · Endoscopy International Open · doi:10.1055/a-2631-7439 · Cited by 1
Kidney Transplantation with Transplant Phases
Puttarajappa, C. M., & Mohan, S. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780197697320.003.0002
Ladapo, J. A., D’Adamo, C. R., Anton, S. D., Sheer, A. J., VandeWeerd, C. L., Vincent, K. R., Wali, S., Vincent, H. K., & Manini, T. M. (2025) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2025.105628
Powell, D. R., Sligtenhorst, I. V., Main, A. J., Jin, H., Carson, K. G., Shi, Z.-C., Swaffield, J. C., Smith, M. G., Harris, A. L., Gopinathan, S., et al. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf196
“Furthermore, discontinuation of incretin agonists results in rapid BW regain, underscoring the need for long-term treatment with these peptide drugs [5, 6].”
Decommodifying and Humanizing Health Care: Revisiting Pellegrino's Ethical Imperative
Fiscella, K. A., Vera, A., & Jenkins, A. (2026) · Milbank Quarterly · doi:10.1111/1468-0009.70084
Health Care Costs and Use of Patients Prescribed Four Different Obesity Medications
Lewis, K. H., Zhang, F., LeCates, R. F., Argetsinger, S., Albert, S., Iyer, G. S., Connolly, J. G., Wharam, J. F., Arterburn, D. E., Ross‐Degnan, D., et al. (2026) · Obesity · doi:10.1002/oby.70208
Fouad, Y. M., Abdelghany, W. A., & Sheemy, R. Y. E. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i5.118303
Access to GLP-1s for Medicare Beneficiaries — A Bridge to Nowhere?
Dusetzina, S. B. (2026) · New England Journal of Medicine · doi:10.1056/nejmp2605694
Self-citationOshman, L. D., Runyon, A., Bal, A. V., Arizaca-Dileo, P. K., Sen, A., Othman, A., Gabison, J. G., Rothberg, A. E., Kraftson, A. T., GRIAUZDE, D., et al. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100304
Marks, B. A., Sales, A. E., Hsu, C. W., Smith, V. A., Meza, R. D., Lewis, K. H., Dusetzina, S. B., Arterburn, D. E., & Maciejewski, M. L. (2026) · JMIR Research Protocols · doi:10.2196/108690
Self-citation
Metadata
- Authors
- Baig, K., Dusetzina, S. B., Kim, D. D., & Leech, A. A.
- Affiliations
- Vanderbilt University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-03-16
- Volume
- 388
- Issue
- 11
- Pages
- 961-963
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4323925813
- Cited by
- 66
- References
- 3
- Citations by year
- 2026: 7 · 2025: 16 · 2024: 26 · 2023: 17
- FWCI
- 10.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Healthcare Policy and Management
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Keywords
- Medicare Part D, anti-obesity drugs, obesity treatment, drug coverage, drug effectiveness, Medicare beneficiaries
- MeSH terms
- Aged, Humans, United States, Anti-Obesity Agents, Insurance Coverage, Uncertainty, Medicare Part D
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.